Merck (MRK) is down -10.8%, or -$10.74 to $89.05. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today’s best-performing ...

He says, if confirmed, he can still earn referral fees from a firm suing Merck. In 2020, as a pandemic raged across the globe, Robert F. Kennedy Jr. took to social media to appeal to his hundreds ...

RAHWAY, N.J., January 28, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly ...

Merck MRK will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $15.56 billion and $1.72 per ...

Robert F. Kennedy Jr. is not qualified to be health and human services secretary for many reasons, chief among them being his years-long unscientific campaign against essential vaccines.

Merck (MRK) announced the U.S. FDA has accepted for priority review a supplemental new drug application seeking approval of Welireg, Merck’s oral hypoxia-inducible factor-2 alpha inhibitor, for ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at Leerink Partners believe that Merck’s Winrevair “should have ...

Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. over the marketing and sale of one of its vaccines. RFK Jr.’s plan—which was ...

Want to brand your business without breaking the bank? The best free logo maker will be an essential tool in your marketing kit - and after testing these completely free logo designers ...

We've been getting creative with the best logo makers for branding your business online. It's difficult to understate the importance of good logo design - it's the quickest way for customers and ...

Robert F. Kennedy Jr., President Trump’s nominee to be health secretary, would have oversight power over the vaccine’s maker, Merck, if confirmed. By Christina Jewett and Sheryl Gay Stolberg ...

Merck's current discounted valuation, and robust pipeline advancements, which tripled over the past 3+ years, present a compelling long-term investment opportunity. Its strong business performance ...